Actelion CFO suddenly replaced with Pierre Fabre exec; Galderma wins FDA nod for rosacea treatment Mirvaso;

@FiercePharma: Sudden CFO departure at Actelion, just as Swiss drug maker wraps up Ceptaris buyout. More | Follow @FiercePharma

@EricPFierce: Swiss CMO Siefried building a manufacturing plant in China. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: From FierceVaccines: Low vaccination rate at megachurch linked to measles outbreak. Story | Follow @CarlyHFierce

> The Swiss drugmaker Actelion ($ATLN) says CFO Andrew Oakley will leave the company next week, to be replaced by Pierre Fabre's current CFO, Andre Muller. Report

> Galderma won FDA approval for its Mirvaso topical gel to treat facial redness in patients with rosacea. Report

> Beef supplier Cargill says it will stop accepting cattle fed with Merck's ($MRK) Zilmax by the end of September, after the drugmaker suspended sales and started investigating safety concerns. Report

> The U.K.'s Cancer Drugs Fund, which helps pay for expensive treatments not approved by cost-effectiveness gatekeepers, will assist more than 16,500 patients this fiscal year, a cancer charity said. Report

> Novo Nordisk ($NVO) launched a $3 million diabetes prevention program in South Dakota, aimed at reducing the incidence of the disease on the Rosebud Sioux Tribe reservation. Report

> Hyderabad, India-based vaccines maker Bharat Biotech launched a typhoid conjugate shot, Typbar-TCV, for children and adults in the domestic market. Report

Medical Device News

@FierceMedDev: Sign up for our new publication, FierceDiagnostics, launching with its first weekly newsletter tomorrow. Sign up here | Follow @FierceMedDev

@DamianFierce: Covidien has opened the doors of a new $21M South Korean R&D shop. More | Follow @DamianFierce

@MarkHFierce: Edwards, fresh from a patent lawsuit victory, is heralding a German injunction on Medtronic CoreValve sales. Story | Follow @MarkHFierce

@MichaelGFierce: Ceptaris nets first-ever FDA approval for topical lymphoma chemo gel. More from FierceDrugDelivery | Follow @MichaelGFierce

> Covidien cuts ribbon on $21M Korean R&D shop. Report

> New sleep apnea treatment devices emerge. Story

> LDR files for $69M IPO following FDA approval. Article

> Volcano buying Medtronic's imaging catheter. News

> Vestagen pulls in $8.25 million for high-tech medical scrub uniforms. Item

Biotech News

@FierceBiotech: Syndax snags $26.6M round for Phase III breast cancer study. More | Follow @FierceBiotech

@JohnCFierce: Patient advocacy or Amgen's blockbuster protection act? Biosimilars bills advance. Report | Follow @JohnCFierce

> Acura investors feel the pain as abuse-deterrence tech flops in PhII. More

> Tiny Catalyst soars after rare disease drug scores 'breakthrough' at FDA. News

Biotech Research News

@EmilyMFierce: Omega-3 alleviates ADHD symptoms in rats. More | Follow @EmilyMFierce

> High copper levels implicated in Alzheimer's disease. Story

> Single injection could provide new treatment for melanoma. Article

> New target to battle Parkinson's discovered. News

> Gene therapy in mice improves Rett syndrome. More

> Sodium 'switch' could provide target to treat brain disorders. Item

Pharma Manufacturing News

> Akorn buys Hi-Tech for $640M to tap manufacturing expertise. Report

> Amarin asks FDA to approve Novasep as Vascepa partner. Story

> Lonza starting job cuts at troubled U.S. biologics plant. Article

> Ontario helps Pillar5 expand plant. Item

> Another Fresenius plant in FDA crosshairs. More

And Finally... How about a marriage drug? Scientists posit that intranasal oxytocin could strengthen long-term relationships. More

Suggested Articles

Novartis said it plans to use the complete response rate data for a U.S. filing in follicular lymphoma in 2021.

Sen. Elizabeth Warren asked the SEC to probe Kodak trades made before the Trump administration unveiled their drug supply deal—and $765M in funding.

Amarin's wild 2020 ride continues with plans to launch its cardiovascular med Vascepa in Europe without a bigger marketing partner.